OBR Green Articles (ASCO GI Conference Coverage)

article

February 2019Edition

At ASCO GI 2019, data from four trials made headlines: Pembrolizumab with and without chemo stole the show in separate trials of advanced esophageal and HER2+ metastatic esophagogastric cancers respectively. We'll keep you guessing on the other two...